---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-030568"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-08-03T11:41:33+00:00"
generated_at: "2026-08-03T11:45:05.274184+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma reports positive safety data from first 3 patients in Phase 2 Danon disease trial

## Summary
- Initial three patients treated safely with RP-A501 at recalibrated dose 3.8×10^13 GC/kg; no TMA or capillary leak syndrome observed.
- Company engaging with FDA to align on path to complete pivotal Phase 2 trial; regulatory update expected H2 2026.
- Comprehensive Danon disease program update on track for H2 2026.
- Phase 2 trial designed as 12-patient single-arm study.

## SEC filing metadata
- accession: 0001140361-26-030568
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-08-03T11:41:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/0001140361-26-030568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/ef20079241_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-030568
- JSON: https://secwatch.observer/filing/0001140361-26-030568.json
- Plain text: https://secwatch.observer/filing/0001140361-26-030568.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.